Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. ICORG 07-12
Conditions
Breast Cancer - Colorectal Cancer - Lung Cancer - Melanoma (Skin) - Pancreatic Cancer
Conditions: official terms
Breast Neoplasms - Colorectal Neoplasms - Lung Neoplasms - Melanoma - Pancreatic Neoplasms
Conditions: Keywords
stage IV melanoma, recurrent melanoma, stage IV non-small cell lung cancer, recurrent non-small cell lung cancer, extensive stage small cell lung cancer, recurrent small cell lung cancer, stage IV breast cancer, recurrent breast cancer, male breast cancer, stage III pancreatic cancer, stage IV pancreatic cancer, recurrent pancreatic cancer, stage IV colon cancer, recurrent colon cancer, stage IV rectal cancer, recurrent rectal cancer
Study Type
Observational
Study Phase
N/A
Study Design
Time Perspective: Prospective
Overall Status
Recruiting
Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer.

PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.
Detailed Description
OBJECTIVES:

Primary

- To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups.

Secondary

- To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy.

OUTLINE: This is a multicenter study.

Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Both
Criteria: DISEASE CHARACTERISTICS:

- Diagnosis of 1 of the following advanced metastatic malignancies:

- Malignant melanoma

- Lung cancer

- Breast cancer

- Pancreatic carcinoma

- Colorectal cancer

- Advanced and/or metastatic disease

- Hormone receptor status not specified

PATIENT CHARACTERISTICS:

- Menopausal status not specified

PRIOR CONCURRENT THERAPY:

- Not specified
Locations
Cork University Hospital
Cork, Ireland
Status: Recruiting
Contact: Contact Person - 353-21-492-1301
Mercy University Hospital
Cork, Ireland
Status: Recruiting
Contact: Contact Person - 021-4271971
Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital
Dublin, Ireland
Status: Recruiting
Contact: Contact Person - 353-1-414-2012
Beaumont Hospital
Dublin, Ireland
Status: Recruiting
Contact: Contact Person - 353-21-492-1301
Mater Misericordiae University Hospital
Dublin, Ireland
Status: Recruiting
Contact: Contact Person - 353-1-858-569
Mater Private Hospital
Dublin, Ireland
Status: Recruiting
Contact: Contact Person - 01 885 8888
St Luke's Hospital
Dublin, Ireland
Status: Active, not recruiting
St. James's Hospital
Dublin, Ireland
Status: Recruiting
Contact: Contact Person - 353-1-410-3545
St. Vincent's University Hospital
Dublin, Ireland
Status: Recruiting
Contact: Contact Person - 353-1-209-4895
University College Hospital
Galway, Ireland
Status: Recruiting
Contact: Contact Person - 353-91-544-805
Letterkenny General Hospital
Letterkenny, Ireland
Status: Recruiting
Contact: Contact Person - consumer.serviceslgh@hse.ie
Mid-Western Cancer Centre at Mid-Western Regional Hospital
Limerick, Ireland
Status: Recruiting
Contact: Contact Person - 353-61-482-542
Waterford Regional Hospital
Waterford, Ireland
Status: Recruiting
Contact: Contact Person - 353-51-842-562
Start Date
August 2008
Sponsors
ICORG- All Ireland Cooperative Oncology Research Group
Source
ICORG- All Ireland Cooperative Oncology Research Group
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page